association of bdnf val66met polymorphism with amphetamine and opioid dependency in azeri population of iran: a case- control study

Background: emerging evidence suggests a link between the val66met polymorphism of brain-derived neurotrophic factor (bdnf) and an increased risk of neurobehavioral disorders (reference here). the present study aims to elucidate the potential relationship between this genotype and the predisposition to amphetamine and opiate dependencies among the iranian azeri population. through rigorous analysis and comprehensive genetic profiling, this research endeavors to contribute valuable insights into the complex interplay between genetic factors and substance dependency in this specific ethnic group. methods: a cohort of 150 participants was recruited for this study, consisting of 133 males and 17 females in the treatment group, alongside 100 controls, comprising 74 males and 26 females. genotyping procedures utilized pcr-rflp genotyping. results: comprehensive analysis revealed no statistically significant differences in the distribution of genotypes and alleles of the bdnf gene polymorphism (rs6265) between the case and control cohorts. the control group's gg and aa genotypes were higher than the case group's, while the control group's ag genotype was lower than the case group's, but statistically significant difference was not showed (p > 0.05). conclusion: the outcomes of this rigorously designed study fail to substantiate a significant correlation between the val66met polymorphism of the bdnf gene and the susceptibility to amphetamine and opiate dependency. this finding adds a new piece of the puzzle to our understanding of genetic predispositions in substance dependence.